Approval for Novo Nordisk diabetes drug

Major diabetes drug Victoza has received a strong boost on the way to approval. The European Medicines Agency gave Novo Nordisk the good news, following a blow from American experts who remain unsure about the safety of the drug .
Following the news, shares in the Danish company climbed 5 per cent in US trading. The diabetes drug company intend to launch the drug this summer across a number of European markets.
The Food and Drug Administration voted 6-6 regarding thyroid tumours found in rats and mice that the drug was tested on. Fears are running high that the FDA will possibly block the drug or at the least delay its launch.
The drug is part of a new class of injectable drugs for people with diabetes, the core function of which is to stimulate insulin release if glucose levels become too high.